Type 2 diabetes, heart failure
Conditions
Interventions
Test group:henagliflozin, 5 mg, Qd
Control group:dapagliflozin, 10 mg, Qd
Sponsors
the First Affiliated Hospital of University of Science and Technology of China
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Agree to participate in the study and sign the informed consent form; (2) Age: 18-75 years old; (3) BMI = 25kg/m2, waist circumference = 80cm (female) or = 90cm (male); (4) Type 2 diabetes meets the diagnostic criteria for diabetes in the Chinese Guide for the Prevention and Treatment of Type 2 diabetes, 2020 edition of the Chinese Medical Association; (5) Meets the diagnostic criteria for HFrEF in the 2018 edition of the Chinese Heart Failure Diagnosis and Treatment Guidelines of the Chinese Medical Association.
Exclusion criteria
Exclusion criteria: (1) Patients allergic to SGLT-2 inhibitor drugs; (2) Glomerular filtration rate (eGFR)180mmHg, diastolic blood pressure>100mmHg); (9) Serious illnesses such as severe anemia, neutropenia, organic heart disease, autoimmune diseases, viral hepatitis, cirrhosis, kidney disease, infections, malignant tumors, and uncontrolled mental illnesses; (10) History of frequent urinary and/or reproductive tract infections (= 3 times/year); (11) Pregnant or lactating patients with plans to conceive within the next year; (12) Participated in other clinical trials within 90 days; (13) Any situation that researchers believe may affect efficacy or safety evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of readmission due to heart failure within 12 months; | — |
Secondary
| Measure | Time frame |
|---|---|
| Glycosylated hemoglobin;left ventricular ejection fraction (LVEF);total cholesterol;Classification of nyha heart function;NTpro-BNP;body weight ;HOMA-IR; | — |
Countries
China
Contacts
Public ContactHao Hu
the First Affiliated Hospital of University of Science and Technology of China
Outcome results
None listed